Terms: = Prostate cancer AND ROS1, ROS, 6098, ENSG00000047936, P08922, MCF3, RP1-179P9_1 AND Treatment
23637 results:
1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract] [Full Text] [Related]
2. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
Lin Y; Xu G; Li L; Xiang J; Zhai L
Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
[TBL] [Abstract] [Full Text] [Related]
3. prostate intra-fraction motion recorded by transperineal ultrasound.
Ballhausen H; Belka C; Li M
Sci Data; 2024 May; 11(1):504. PubMed ID: 38755158
[TBL] [Abstract] [Full Text] [Related]
4. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed prostate cancer.
Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
[TBL] [Abstract] [Full Text] [Related]
5. WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling.
Cheng J; Huo D; Zhang Z; Zhang J; Dong B; Liu Z; Zhou Z; Lu Y
Med Oncol; 2024 May; 41(6):151. PubMed ID: 38743149
[TBL] [Abstract] [Full Text] [Related]
6. First in vitro measurement of VHEE relative biological effectiveness (RBE) in lung and prostate cancer cells using the ARES linac at DESY.
Wanstall HC; Burkart F; Dinter H; Kellermeier M; Kuropka W; Mayet F; Vinatier T; Santina E; Chadwick AL; Merchant MJ; Henthorn NT; Köpke M; Stacey B; Jaster-Merz S; Jones RM
Sci Rep; 2024 May; 14(1):10957. PubMed ID: 38740830
[TBL] [Abstract] [Full Text] [Related]
7. A bicentric retrospective study of the correlation of EAU BCR risk groups with
Poterszman N; Merlin C; Margail C; Ouvrard E; Imperiale A; Somme F
Sci Rep; 2024 May; 14(1):10908. PubMed ID: 38740809
[TBL] [Abstract] [Full Text] [Related]
8. Nanocarrier - Mediated Salinomycin Delivery Induces Apoptosis and Alters EMT Phenomenon in prostate Adenocarcinoma.
Kanchan S; Marwaha D; Tomar B; Agrawal S; Mishra S; Kapoor R; Sushma ; Jha G; Sharma D; Bhatta RS; Mishra PR; Rath SK
AAPS PharmSciTech; 2024 May; 25(5):104. PubMed ID: 38724836
[TBL] [Abstract] [Full Text] [Related]
9. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract] [Full Text] [Related]
10. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
Leclercq L; Bastide C; Lechevallier E; Walz J; Charvet AL; Gondran-Tellier B; Campagna J; Savoie PH; Long-Depaquit T; Daniel L; Rossi D; Pignot G; Baboudjian M
Fr J Urol; 2024 Mar; 34(2):102571. PubMed ID: 38717459
[TBL] [Abstract] [Full Text] [Related]
11. Cinobufotalin Capsule Combined with Zoledronic Acid in the treatment of Pain Symptoms and Clinical Efficacy in prostate cancer Patients with Bone Metastases: A Retrospective Study.
Zhang F; Dong Y; Chen F; Niu M; Liu Z; Wang C
Arch Esp Urol; 2024 Apr; 77(3):242-248. PubMed ID: 38715164
[TBL] [Abstract] [Full Text] [Related]
12. Identifying risk factors for hypoxemia during emergence from anesthesia in patients undergoing robot-assisted laparoscopic radical prostatectomy.
Zhang Q; Zhu L; Yuan S; Lu S; Zhang X
J Robot Surg; 2024 May; 18(1):200. PubMed ID: 38713381
[TBL] [Abstract] [Full Text] [Related]
13. A Unique Approach: Biomimetic Graphdiyne-Based Nanoplatform to Treat prostate cancer by Combining Cuproptosis and Enhanced Chemodynamic Therapy.
Xie W; Zhang Y; Xu Q; Zhong G; Lin J; He H; Du Q; Tan H; Chen M; Wu Z; Deng Y; Han Z; Lu J; Ye J; Zou F; Zhuo Y; Zhong W
Int J Nanomedicine; 2024; 19():3957-3972. PubMed ID: 38711614
[TBL] [Abstract] [Full Text] [Related]
14. Irradiated microparticles suppress prostate cancer by tumor microenvironment reprogramming and ferroptosis.
Deng Z; Li B; Yang M; Lu L; Shi X; Lovell JF; Zeng X; Hu W; Jin H
J Nanobiotechnology; 2024 May; 22(1):225. PubMed ID: 38705987
[TBL] [Abstract] [Full Text] [Related]
15. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract] [Full Text] [Related]
16. Survival benefit of radical prostatectomy in patients with advanced TURP-diagnosed prostate cancer: a population-based real-world study.
Lin D; Lin L; Ye L; Li T; Wei Y; Li L
BMC Surg; 2024 May; 24(1):134. PubMed ID: 38702689
[TBL] [Abstract] [Full Text] [Related]
17. Navigating through the coordination preferences of heavy alkaline earth metals: Laying the foundations for
Franchi S; Madabeni A; Tosato M; Gentile S; Asti M; Orian L; Di Marco V
J Inorg Biochem; 2024 Jul; 256():112569. PubMed ID: 38701687
[TBL] [Abstract] [Full Text] [Related]
18. On the necessity of specialized knowledge-based models for SBRT prostate treatments plans.
Scaggion A; Cavinato S; Dusi F; El Khouzai B; Guida F; Paronetto C; Rossato MA; Sapignoli S; Scott ASA; Sepulcri M; Paiusco M
Phys Med; 2024 May; 121():103364. PubMed ID: 38701626
[TBL] [Abstract] [Full Text] [Related]
19. Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
Ding W; Chen L; Xia J; Pei B; Song B; Li X
Medicine (Baltimore); 2024 May; 103(18):e38010. PubMed ID: 38701318
[TBL] [Abstract] [Full Text] [Related]
20. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
[TBL] [Abstract] [Full Text] [Related]
[Next]
